[Featured Stock] GobioLab Surges on News of US Patent Registration

As of 9:20 AM on the 9th, GobioLab's stock price on the KOSDAQ market is recording 5,990 KRW, up 17.22% compared to the previous day's closing price. This appears to be due to the announcement of the registration of a U.S. patent for a liver damage treatment material released the day before.

GobioLab, a company specializing in microbiome drug development, announced yesterday that the registration of a U.S. patent has been decided for a human microbiome-derived liver damage treatment material used in the treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). MASLD refers to liver diseases related to metabolic abnormalities, ranging from simple steatosis to progressive fibrosis and cirrhosis. Its prevalence is increasing similarly to the rise in obesity and metabolic syndrome patients.

GobioLab explained that by utilizing its proprietary functional strains of the genus Ruminococcus spp., it confirmed the liver damage improvement effects in patients with insulin resistance. Based on human-derived strains, side effects have been significantly reduced, and it can be developed into an oral formulation, making it convenient to take.

A GobioLab representative said, "We have obtained patents for this strain in a total of six countries, including South Korea, Japan, China, Russia, Australia, and the United States, which has the largest market size." He added, "Through the acquisition of global rights in earnest, not only can we accelerate market entry, but we can also claim exclusive rights in the highly expandable therapeutic market."

Meanwhile, GobioLab recorded sales of 68.4 billion KRW and an operating loss of 6.9 billion KRW last year based on consolidated financial statements. Most of the sales came from WeBiome, a health functional food subsidiary established in 2022 in partnership with Emart. The company is discovering and commercializing high-functional microbial materials tailored to major target functions such as women's health, immunity, metabolic diseases, and mental health.